

AUTHOR INDEX

Volume 43

January to June 1991

- Adoni, A., 77
 Albert, A.E., 167
 Albring, M., 101
 Andersch, B., 111
 Andrade, A.T.L., 241
 Ansari, A.S., 187, 485
 Ansbacher, R., 139
 Antúnez, O., 45
 Apelo, R., 33
 Aravena, R., 335
 Atsma, W.J., 23
 Back, D.J., 305, 317
 Barcelloña, P.S., 485
 Baudhuin, P., 387
 Belsey, E.M., 241, 361, 375, 387, 401
 Ben Chetrit, A., 77
 Bhaduri, A.P., 507
 Bhat, N., 507
 Boeck, L., 45
 Bordon, R., 423
 Brill, K., 101
 Brinton, L.A., 581
 Brosens, I., 361, 375, 387
 Bunce, S., 33
 Buytaert, Ph., 413
 Cárdenas, H., 335
 Carta, Q., 423
 Casado, M.E., 335
 Cerza, S., 251
 Chakraborty, S., 273
 Chi, I-c, 33
 Chretien, F.C., 55
 Cornillie, F., 361, 387
 Courtoy, P.J., 387
 Croxatto, H.B., 335
 Croxtall, J.D., 401
 Csemiczky, G., 149
 Custo, C., 251
 d'Arcangues, C., 361, 401
 Díaz, S., 335
 Díaz-Sánchez, V., 45
 Dibbelt, L., 1
 Diczfalussy, E., 201
 Donovan, B., 177
 Dubois, R., 55
 Dwivedi, A., 507
 Elder, M., 129, 361, 401
 Elstein, M., 129
 Eneroth, P., 447
 Fang, R-y, 287
 Farr, G., 229
 Fioretti, P., 23
 Fruzzetti, F., 23
 Gates, D., 33
 Gennarelli, G.L., 423
 Gerofi, J., 177
 Goldenberg, R.L., 325
 Goodson, P., 121
 Graves, W., 167
 Green, A., 653
 Green, S., 305
 Haeberli, A., 435
 Haller, H., 229
 Hardy, E., 121
 Hatcher, R.A., 167
 Heimann, S., 1
 Hourihan, H., 361, 375
 Inauen, W., 435
 Jackson, J.R., 325
 Jayaprakash, D., 187
 Johannisson, E., 361, 459
 Jonsson, B., 447
 Jütting, G., 1
 Kamboj, V.P., 507
 Kaur, J., 83, 295
 Kim-Bjorklund, T., 459
 K .g, R.J.B., 527
 Klipping, C.O., 1
 Knuppen, R., 1
 Kohler, C.L., 325
 Kumar, M., 187
 Lammers, P., 23
 Landgren, B-M, 149, 447, 459
 Lasso de la Vega, J., 33
 Lawson, J.P., 129
 Lohiya, N.K., 187, 485
 Mahato, S.B., 475
 Mant, T., 317
 Marbaix, E., 387
 Martin, C., 317
 Mehrotra, P.K., 507
 Melis, G.B., 23
 Merchant, P., 67
 Millar, E., 317
 Milne, R., 667
 Milsom, I., 111
 Miranda, P., 335
 Mirghani, O.A., 353
 Morrison, P., 317

CONTRACEPTION

- Nicoletti, I., 23
 Noguera, M., 45
 Norpoth, T., 101
 Nuttall, I.D., 129
 Orme, M., 305, 317
 Pakrashi, A., 273, 475
 Pal, B.C., 475
 Panser, L.A., 91
 Parikka-Olexik, H., 1
 Patel, K.L., 67
 Patel, L., 401
 Perovic, M., 229
 Phipps, W.R., 91
 Pruthi, J.S., 83
 Qian, L-j, 263
 Rajalakshmi, M., 83, 295
 Ramakrishnan, P.R., 83, 295
 Ramos, R., 33
 Randic, L., 229
 Ray, H., 475
 Renier, M., 413
 Ricci, C., 23
 Richards, J.M., Jr., 325
 Rivera, R., 33
 Rosenberg, L., 643
 Rowe, P.J., 241
 Ryan, W.G., 325
 Saitto, C., 251
 Saltzman, W.M., 497
 Sang, G-w, 263
 Schiappacasse, V., 335
 Schlesselman, J.J., 557
 Schnitker, J., 101
 Scoccia, G., 251
 Seth, M., 507
 Shahani, S., 67
 Sharma, D.N., 83
 Sharma, K., 187
 Sharma, S., 187
 Shaw, S.T., Jr., 241
 Shelley, G., 177
 Sheppard, B., 361, 375
 Shukla, R., 507
 Skegg, D.C.G., 521
 Souza, J.P., 241
 Srivastava, R.P., 507
 Stanford, J.L., 543
 Straub, P.W., 435
 Sullivan, M.H.F., 401
 Sundell, G., 111
 Taha, A.Z., 353
 Tena, L.B., 497
 Thomas, D.B., 597, 695
 Tjia, J., 317
 Trossarelli, G.F., 423
 Vargas, L., 45
 Vessey, M., 667
 Volpec, R., 251
 Ward, S., 305
 Weng, L-j, 263
 White, J., 361, 401
 Xu, D., 263
 Yang, B-z, 287
 Yang, J., 161
 Zhang, J-y, 263
 Zhang, Y-p, 287
 Zhao, Z., 161
 Zheng, H-z, 263
 Zhou, H-j, 287

SUBJECT INDEX

Volume 43

January-June, 1991

- Acacia auriculiformis triterpene saponins, effect on sperm motility, 475
- Accessory gland function,
 effect of 20 Aet-1 (monkey), 83
 effect of testosterone enanthate (monkey), 83
- Adenomatous hyperplasia, relation to oral contraception, 557
- 20 Aet-1 (testosterone-trans-4-n-butyl cyclohexyl-carboxylate)
- Antifertility effect, Malvaviscus konzattii flower extract (male rat), 273
- Arachidonic acid metabolite production, effect of levonorgestrel, 401
- Attitudes of rural mothers toward family spacing methods, 353
- Benign breast disease, relation of OC use and risk of breast cancer, 597
- Benzalkonium chloride, permeation through biocompatible polymers, 497
- Bile and gallbladder function, effect of OC use, 667
- Bioavailability,
 ethinylestradiol, 45
 eutectic ethinylestradiol-cholesterol, 45
- Biochemical changes, effect of Malvaviscus konzattii flower extract (male rat), 273
- Biochemical effects, use of ethinyl estradiol + desogestrel, 435
- Biocompatible polymers, spermicide permeation, 497
- Bioequivalence testing for therapeutic equivalence of oral contraceptives, 139
- Biological profile, use of compound 85/83 (hamster, rat), 507
- Biological testing, use of triterpene saponins from Acacia auriculiformis, 475
- Bleeding pattern,
 use of ethinylestradiol + gestodene, 101, 413
 use of ethinylestradiol + levonorgestrel, 263
- Blood coagulation, effect of ethinyl estradiol + desogestrel, 435
- Blood-subendothelium interaction, effect of ethinyl estradiol + desogestrel, 435
- Body iron stores and menstrual blood loss, 241
- Brand-name vs generic oral contraceptives, bioequivalence testing, 139
- Breakage of condoms during use, 167
- Breakage of condoms in use, relationship of tensile testing, 177
- Breast, contraceptive agents and neoplasia, 527
- Breast cancer,
 relation to formulations and constituents of oral contraceptives, 597
 relative risk estimates in relation to OC use, 597
 relative risk estimates in relation to OC use in developing and developed countries, 695
- Breast cancer and oral contraceptives, epidemiologic review, 597
- Buserelin, alone or in combination with testosterone enanthate, antispermatogenic activity, reversibility and toxicity (monkey), 197

CONTRACEPTION

- Carbohydrate metabolism, effect of ethinylestradiol + gestodene, 423
- CBG (corticosteroid-binding globulin)
- CBG level,
 - effect of ethinyl estradiol + desogestrel, 1
 - effect of ethinyl estradiol + gestodene, 1
- Cervical adenocarcinoma, relationship to oral contraceptives, 581
- Cervical carcinoma, relative risk estimates in relation to OC use in developing and developed countries, 695
- Cervical mucus, effect of norgestrel acetate, 55
- Cervical mucus composition, effect of various IUDs, 447
- Cervical neoplasia,
 - relationship to oral contraceptives, 581
 - relative risk estimates in relation to OC use, 581
- Cervix, contraceptive agents and neoplasia, 527
- Chlorhexidine, permeation through biocompatible polymers, 497
- Cholangiocarcinoma,
 - relation to OC use, 643
 - relative risk estimates in relation to OC use in developing and developed countries, 695
- Clinical chemistry,
 - effect of Buserelin (monkey), 187
 - effect of Buserelin + testosterone enanthate (monkey), 187
- Clinical experience, use of ethinylestradiol + gestodene, 101
- Clinical investigations, use of toluidamine (monkey), 485
- Clinical study,
 - copper-bearing Lippes Loop, 229
 - Lippes Loop, 229
- Coagulatory factors, effect of ethinylestradiol dose in oral contraceptives, 23
- Colon cancer, relationship to OC use, 667
- Colorectal/rectal cancer,
 - relationship to OC use, 667
 - relative risk estimates in relation to OC use, 667
- Complaints, use of levonorgestrel-releasing intravaginal ring, 129
- Compound 85/83 (3-amino-6,7-dimethoxy-1H-pyrazolo [3,4-b] quinoline, effect on pregnancy (guinea pig, hamster, rat), 507
- Condom use and breakage, 167
- Condoms,
 - breakage rates, 167
 - motivation for use, 167
 - relationship between tensile testing and breakage in use, 177
- Contraception and pregnancy outcome, 111
- Contraceptive efficacy, lactational amenorrhea, 335
- Contraceptive method accepted and perception of information received, 121
- Contraceptive methods currently in use, 201
- Contraceptive practices, rural village settings, 353
- Contraceptive prevalence, reproductive health and future, 201
- Copper-bearing Lippes Loop, clinical study, 229
- Copper-containing Nova-T, effect on composition of cervical mucus, 447
- Corpus luteum, effect of norethisterone, 459

- Cutaneous melanoma,
 - relation to OC use, 653
 - relative risk estimates in relation to OC use, 653
- Cyproterone acetate, effect on epididymis and spermatozoa (monkey), 295
- Developed vs developing countries,
 - influence of OC use on risk of neoplasms, 695
 - relationship between OC use and breast cancer, 597
- Discontinuations,
 - OC use, 111
 - use of ethinyl oestradiol + gestodene, 413
 - use of levonorgestrel-releasing intravaginal ring, 129
- DL111-IT (3-(2-ethyl phenyl)-5-(3-methoxy phenyl)-1H-1,2,4-triazole), subsequent embryotoxic and teratogenic effects (rat), 287
- Duration of OC use and relation to risk of breast cancer, 597
- Effectiveness, use of ethinyl oestradiol + gestodene, 413
- Efficacy, use of ethinylestradiol + gestodene, 101
- Embryotoxicity, subsequent gestation after administration of DL111-IT (rat), 287
- Endocrine parameters, effect of β -hCG vaccine formulations, 67
- Endometrial arachidonic acid metabolites, effect of levonorgestrel, 401
- Endometrial cancer,
 - relative risk estimates in relation to OC use, 557
 - relative risk estimates in relation to OC use in developing and developed countries, 695
- Endometrial lysosomal enzymes, effect of levonorgestrel, 387
- Endometrial morphology,
 - effect of levonorgestrel, 361
 - effect of norethisterone, 459
- Endometrial vasculature, effect of levonorgestrel, 375
- Endometrium,
 - contraceptive agents and neoplasia, 527
 - effect of norethisterone, 459
 - oral contraceptives and neoplasia, 557
- Environmental health and reproductive health, 201
- Epididymal tubules culture system (monkey), 295
- Epididymis, effect of cyproterone acetate (monkey), 295
- Estrogen action, relevant to neoplasia, 527
- Estrogen replacement therapy, risk of endometrial cancer, 557
- Ethinylestradiol, absorption study, 45
- Ethinyl estradiol + desogestrel,
 - effect of deliberate omission of pill intake, 149
 - effect on blood coagulation and thrombogenesis, 435
 - effect on coagulatory factors, 23
 - effect on SHBG and CBG levels, 1
 - high and low estrogen dose, 435
 - pharmacokinetic parameters for ethinyl estradiol, 1
- Ethinyl estradiol + gestodene,
 - clinical experience, 101
 - clinical trial, 413
 - effect on carbohydrate metabolism, 423
 - effect on coagulatory factors, 23
 - effect on SHBG and CBG levels, 1
 - pharmacokinetic parameters for ethinyl estradiol, 1

CONTRACEPTION

- Ethinyl estradiol + levonorgestrel,
 - clinical experience, 263
 - effect of deliberate omission of pill intake, 149
 - effect on coagulatory factors, 23
- Ethinylestradiol dose in oral contraceptives, effect on haemostatic system, 23
- Ethinyl estradiol level,
 - following ethinyl estradiol + desogestrel, 1
 - following ethinyl estradiol + gestodene, 1
- Ethinylestradiol-cholesterol eutectic combination, absorption study, 45
- Ethinylestradiol, pharmacokinetics, 305
- Ethinylestradiol + desogestrel, effect on pharmacokinetics of ethinylestradiol, 305
- Ethinylestradiol + gestodene, effect on pharmacokinetics of ethinylestradiol, 305
- Ethinylestradiol + levonorgestrel, interaction with temafloxacin, 317
- Fallopian tube, effect of norethisterone, 459
- Family spacing attitudes and practices, 353
- Filshie clip via minilaparotomy, postpartum tubal sterilization, 33
- Follicular growth,
 - effect of ethinylestradiol + desogestrel, 149
 - effect of ethinylestradiol + levonorgestrel, 149
- Gallbladder cancer, relative risk estimates in relation to OC use in developing and developed countries, 695
- Gallbladder-extrahepatic bile duct cancer,
 - relationship to OC use, 667
 - relative risk estimates in relation to OC use, 667
- Generic vs brand-name oral contraceptives, bioequivalence testing, 139
- Haemostatic system, effect of ethinylestradiol dose in oral contraceptives, 23
- β -hCG vaccines, effect on endocrine parameters, 67
- Hematologic effects, use of ethinyl estradiol + desogestrel, 435
- Hematologic indices and menstrual blood loss, effect of OC use, 241
- Hepatocellular adenoma, relation to OC use, 643
- Hepatocellular carcinoma, relation to OC use, 643
- Hormonal levels, effect of β -hCG vaccine formulations, 67
- Hormonal profile,
 - compound 85/83 (rat), 507
 - effect of Malvaviscus conzattii flower extract (male rat), 273
- Implant contraceptive, levonorgestrel, 121
- Interchangeability of oral contraceptives, generic vs brand-name products, 139
- Intrauterine device (IUD),
 - Anticon, 251
 - copper T, 251
 - copper-bearing Lippes Loop, 229
 - copper-containing Nova-T, 447
 - Gravigard, 251

- levonorgestrel-releasing Nova-T, 447
- Lippes Loop D, 229
- management following uterine perforation, 77
- mechanical resistance assessment, 251
- Nova-T, 251, 447
- TCu 200, 121
- IUD (intrauterine device)
- Kidney cancer, relationship to OC use, 667
- Lactational amenorrhea, contraceptive efficacy, 335
- Levonorgestrel-releasing Nova-T, effect on composition of cervical mucus, 447
- Levonorgestrel-releasing vaginal ring,
 - effect on endometrial vascular features, 375
 - effect on endometrium, 361
 - effect on lysosomal enzymes in endometrium, 387
 - efficacy and acceptability, 129
 - prostaglandin production in endometrium, 401
- LH-RH (luteinizing hormone-releasing hormone)
- LH-RH agonist, Buserelin, 187
- Lippes Loop D, clinical study, 229
- Liver, oral contraceptives and neoplasia, 527, 643
- Liver cancer,
 - relative risk estimates in relation to OC use, 643
 - relative risk estimates in relation to OC use in developing and developed countries, 695
- Luteal function,
 - effect of ethinylestradiol + desorgestrel, 149
 - effect of ethinylestradiol + levonorgestrel, 149
- Lysosomal enzymes in endometrium, effect of levonorgestrel, 387
- Malvaviscus conzattii flower extract, effect on fertility (male rat), 273
- Mast cell numbers, effect of levonorgestrel, 375
- Mechanical resistance assessment, IUDs, 251
- Melanocytic nevi, relation to OC use, 653
- Melanoma,
 - effect of steroid hormones, 653
 - relation to OC use, 653
- Menstrual blood loss and body iron stores, 241
- Menstrual status postpartum, effect on probability of pregnancy, 335
- Mental health, impact of tubal sterilization, 325
- Neoplasia and oral contraceptives, 521, 527, 543, 557, 581, 597, 643, 653, 557, 695
- Neoplasms, influence of OC use on risk in developing and developed countries, 695
- Nomegestrol acetate, effect on cervical mucus, 55
- Nonoxynol-9,
 - permeation through biocompatible polymers, 497
 - quantitative analysis in blood, 161
- Nonoxynol-9-releasing vaginal ring, 497
- Norethisterone, effect on endometrium, Fallopian tube and corpus luteum, 459
- Norplant^R, study of acceptors, 121
- Nova-T, effect on composition of cervical mucus, 447
- Nursing status, effect on probability of pregnancy, 335
- OC (oral contraceptive)
- Omission of oral contraceptive pill intake, effect on follicular growth and luteal function, 149

CONTRACEPTION

- Oral contraceptive (OC),
 - ethinyl estradiol + desogestrel, 1, 23, 149, 435
 - ethinyl estradiol + gestodene, 1, 23, 101, 413, 423
 - ethinylestradiol + levonorgestrel, 317
 - norethisterone, 459
 - triphasic ethinylestradiol + levonorgestrel, 23, 149, 263
- Oral contraceptive use, effect on pelvic inflammatory disease, 91
- Oral contraceptives, bioequivalence testing for therapeutic equivalence, 139
- Oral contraceptives and neoplasia, 521, 527, 543, 557, 581, 597, 643, 653, 667, 695
- Organ culture of epididymal tubules (monkey), 295
- Ovarian cancer,
 - relative risk estimates in relation to OC use, 543
 - relative risk estimates in relation to OC use in developing and developed countries, 695
- Ovary, contraceptives and neoplasia, 527, 543
- Pelvic inflammatory disease, effect of OC use, 91
- Perception of information received and contraceptive method accepted, 121
- Permeation through biocompatible polymers, spermicides, 497
- Pharmacokinetics,
 - ethinyl estradiol, 1, 45, 305
 - eutectic ethinylestradiol-cholesterol, 45
- Pituitary disorders, relationship to OC use, 667
- Pituitary tumours,
 - relationship to OC use, 667
 - relative risk estimates in relation to OC use, 667
- Pituitary-ovarian axis, effect of β -hCG vaccine formulations, 67
- Postpartum tubal sterilization, 33
- Pregnancy, effect of compound 85/83 (guinea pig, hamster, rat), 507
- Pregnancy history and prevalence of contraception, 111
- Pregnancy probability,
 - according to postpartum menstrual status, 335
 - nursing women, 335
- Pregnancy rate, postpartum tubal sterilization, 83
- Progestin action, relevant to neoplasia, 527
- Progestins, potency, 527
- Prostaglandin production in endometrium, effect of levonorgestrel, 401
- Psychosocial impact, tubal sterilization, 325
- Reproductive health, 201
- Resistance to mechanical fatigue, IUDs, 251
- Risk factors, influence on oral contraceptives and breast cancer, 597
- SHBG (sex hormone-binding globulin)
- SHBG level,
 - effect of ethinyl estradiol + desogestrel, 1
 - effect of ethinyl estradiol + gestodene, 1
- Side effects,
 - use of ethinyl estradiol + desogestrel, 435
 - use of ethinylestradiol + gestodene, 101, 413
 - use of ethinylestradiol + levonorgestrel, 263
- Skin neoplasia and oral contraceptives, 653
- Sperm motility, effect of triterpene saponins from Acacia auriculiformis, 475

- Spermatogenesis,
 - effect of Buserelin (monkey), 187
 - effect of Buserelin + testosterone enanthate (monkey), 187
 - effect of *Malvaviscus conzattii* flower extract (rat), 271
 - effect of tolnidamine (monkey), 485
- Spermatozoa,
 - effect of cyproterone acetate (monkey), 295
 - effect of triterpene saponins from *Acacia auriculiformis*, 475
- Sterilization, tubal occlusion during postpartum hospitalization, 33
- TCu 200, study of acceptors, 121
- Temafloxacin, interaction with ethinylestradiol + levonorgestrel, 317
- Tensile testing, condoms, 177
- Teratogenicity, subsequent gestation after administration of DL111-IT (rat), 287
- Terminations, use of ethinylestradiol + levonorgestrel, 263
- Testes,
 - effect of Buserelin (monkey), 187
 - effect of Buserelin + testosterone enanthate (monkey), 187
 - effect of tolnidamine (monkey), 485
- Testosterone enanthate, effect on accessory gland (monkey), 83
- Testosterone-trans-4-n-butyl cyclohexyl-carboxylate (20 Aet-1),
 - effect on accessory gland function (monkey), 83
- Thrombogenesis, effect of ethinyl estradiol + desogestrel, 435
- Time in woman's life OC use initiated and relation to risk of breast cancer, 597
- Tissue plasminogen activator, effect of levonorgestrel, 375
- Tolnidamine (1-[4-chloro-2-methylphenyl)methyl]-1H-indazole-3-carboxylic acid), effect on spermatogenesis (monkey), 485
- Translocation of an IUD, management, 77
- Triphasic ethinylestradiol + levonorgestrel,
 - clinical experience, 263
 - effect of deliberate omission of pill intake, 149
 - effect on coagulatory factors, 23
- Tubal sterilization,
 - postpartum, 33
 - psychosocial impact, 325
- Uterine corpus, oral contraceptives and neoplasia, 557
- Uterine fibroids, effect of oral contraceptives, 557
- Uterine perforation by an IUD, management, 77
- Uterine sarcoma,
 - relation to oral contraception, 557
 - relative risk estimates in relation to OC use in developing and developed countries, 695
- Vaginal ring,
 - releasing levonorgestrel, 129, 361, 375, 387, 401
 - releasing nonoxynol-9, 497
- Vascular subendothelium (rabbit) exposed to flowing blood, effect of ethinyl estradiol + desogestrel, 435